APA (7th ed.) Citation

Leypoldt, L., Tichy, D., Besemer, B., Hänel, M., Raab, M., Mann, C., . . . Weisel, K. C. (2024). Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. Journal of clinical oncology, 42(1), . https://doi.org/10.1200/JCO.23.01696

Chicago Style (17th ed.) Citation

Leypoldt, Lisa, et al. "Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-risk Newly Diagnosed Multiple Myeloma." Journal of Clinical Oncology 42, no. 1 (2024). https://doi.org/10.1200/JCO.23.01696.

MLA (9th ed.) Citation

Leypoldt, Lisa, et al. "Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-risk Newly Diagnosed Multiple Myeloma." Journal of Clinical Oncology, vol. 42, no. 1, 2024, https://doi.org/10.1200/JCO.23.01696.